Royalty Financing: Sell Future Drug Royalties, Not Shares

When a biotech owns a drug but needs cash to fund the next trial, it has three doors: issue new shares, take on debt, or sell something. Most investors only know the first two. The third door, selling the future royalty stream on a drug, is a $30 billion-plus market most retail investors have never heard of, and it is how single-asset companies fund late-stage trials without touching their share count.

The one-sentence answer: sell a percentage of future net sales in exchange for cash today, no dilution, no repayment obligation. Here is how it works and how to invest on either side of the trade.

Step 1: Understand what a royalty actually is

A royalty is a percentage of a drug’s net sales paid to whoever owns the royalty right. The rate is typically 5% to 10% for an approved or late-stage drug. The royalty has a term, and almost always a cap: payments stop once the buyer has collected a fixed multiple of what they paid.

A real cap in practice: in December 2025, Denali Therapeutics sold Royalty Pharma a 9.25% royalty on worldwide net sales of tividenofusp alfa, its Hunter syndrome therapy, for $275 million. The royalty stops paying at a 3.0x multiple, or 2.5x if that threshold is hit by early 2039. Denali keeps the drug, keeps most of the upside, and banked $275 million without issuing a share.

Step 2: Know why companies sell royalties instead of issuing shares

Selling a royalty is non-dilutive. Existing shareholders keep their ownership percentage, unlike an equity raise. It has no repayment obligation, unlike debt, so there is no covenant to breach and no interest to service. And it transfers no clinical risk: the company keeps the drug and keeps most of the economics if the drug crosses $1 billion in annual sales.

The trade-off is cost. The buyer is paying cash today for cash flows that arrive over a decade, so the seller gives up a chunk of future upside. For a pre-revenue biotech with a strong asset and a weak balance sheet, that is often the cheapest capital available. The dilution math is worse: a $150 million raise at a $500 million market cap costs roughly 25% to 30% of the company once you count the offering discount and the announcement drop. For the full picture, see the dilution survival guide.

Step 3: Understand the aggregator model

Royalty Pharma (RPRX) is the giant in this niche, a $30 billion business by its own framing. It buys diversified baskets of drug royalty streams, so its cash flows are steadier and less binary than any single biotech’s. In Q1 2026 it reported $887 million in royalty receipts, up 13% year over year, driven by Tremfya, Voranigo, and Evrysdi. It guided 2026 portfolio receipts to $3.325 billion to $3.45 billion. The company is worth roughly $33 billion to $35 billion in market cap.

That diversification is the point. A royalty on one drug is a single cash flow that can go to zero on a CRL or a patent cliff. Royalty Pharma holds dozens, so a failed drug is a rounding error. For how a royalty asset slots into a buyout, see the takeover-targets M&A screen.

Step 4: Know the newer structures

Classic royalty sales are giving way to synthetic royalties and revenue-interest financing, where healthcare credit funds and firms like Blackstone advance cash against a fixed percentage of revenue for a set term, then the percentage reverts to zero. The newer structures blur the line between debt and royalty, and they are why a single company can raise money against a portfolio, not just one drug.

Revolution Medicines signed a $2 billion flexible funding agreement with Royalty Pharma, taking up to $1.25 billion in exchange for tiered royalties on daraxonrasib for 15 years. The royalty rate steps down as sales grow and hits zero above $8 billion in annual sales. The structure lets a company finance a launch without a fixed debt maturity hanging over the quarter.

Step 5: Evaluate a royalty asset like an investor

Three drivers decide whether a royalty stream is a good asset. First, sales trajectory: is the underlying drug still growing, or is it post-peak and facing a patent cliff? Second, durability: how long do the patents and regulatory exclusivity last? Third, the royalty rate itself, and the cap, which sets the ceiling on total payout.

A royalty on a drug growing past $1 billion in annual sales can be a better risk-adjusted return than the underlying stock, because you get the cash flows without the clinical binary risk of the next trial. But you also get no equity upside if the company gets acquired at a premium. This is where the licensing deal mechanics overlap, so read the licensing deal economics guide to see how royalties differ from upfront and milestone payments.

Common mistakes

Treating the royalty multiple as guaranteed. The 3.0x cap on the Denali deal only pays out if tividenofusp alfa actually launches and sells. The multiple is a ceiling, not a promise.

Ignoring concentration risk. A royalty on a single drug is a single cash flow. If that drug gets a CRL, the royalty is worth close to zero.

Confusing a royalty sale with a licensing deal. A licensing deal is an upfront payment plus milestones plus royalties and usually transfers rights to a partner. A royalty sale transfers only the cash-flow stream, and the seller keeps the drug.

Final checklist

• What is the royalty rate, and what is the cap or multiple that ends the payments?
• Is the underlying drug’s sales trajectory growing or post-peak?
• How durable are the patents and exclusivity?
• Is the seller diluting equity instead, and at what cost?
• For royalty aggregators like Royalty Pharma, how diversified is the basket?

Royalty financing is the anti-dilution door. It costs future upside, but for a biotech with a real asset and a thin balance sheet, it is often the cheapest money in the building, and for an investor, a diversified royalty basket is a lower-binary way to own biotech cash flows without owning the clinical risk.